Earnings6 reported quarters · next on Feb 25, 2027
Earnings
Quarter
EPS
EPS expected
Revenue
Revenue expected
Result
Q3 FY2026reported Nov 5, 2026
-$0.91
-$0.80
$7.2M
$9.7M
EPS miss, GAAPRevenue miss
Q2 FY2026reported Aug 6, 2026
-$0.80
-$0.80
$7.7M
$13.0M
EPS in line, GAAPRevenue miss
Q1 FY2026reported May 11, 2026
-$0.81
-$0.92
$15.0M
$13.8M
EPS beat, GAAPRevenue beat
Q4 FY2025reported Feb 26, 2026
-$0.83
-$0.99
$23.0M
$12.0M
EPS beatRevenue beat
Q3 FY2025reported Nov 6, 2025
-$0.92
-$1.02
$13.8M
$12.2M
EPS beat, GAAPRevenue beat
Q2 FY2025reported Aug 7, 2025
-$0.99
-$1.03
$14.2M
$14.1M
EPS beat, GAAPRevenue in line
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Each firm's latest price target on NTLA, newest first
Firm
Rating
Target
Action
Date
Barclays
Underweight
$8
Initiated
Wedbush
Neutral
$13
Target set
Evercore ISI
Outperform
$24
Target set
Wolfe Research
Underperform
$9
Target set
Bernstein
Market Perform
$17
Target set
Chardan
Buy
$30
Target set
Morgan Stanley
Equal Weight
$15
Target set
Baird
Neutral
$13
Raised from $7
H.C. Wainwright
Buy
$25
Target set
Each firm's latest target from the past year, with the rating stated with its note or within three days of it. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.
7 other firms rated NTLA in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 12, 2026.
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
13F filings13F positions as of Jun 30, 2026
Institutional holders
330 institutions reported Intellia Therapeutics shares in 13F filings for Jun 30, 2026.
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
2 of the 97 fund managers we track list NTLA shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (9)
Insider
Event
Shares
Date
Jing L. MarantzEVP, Chief Medical Officer
Stock award
474,883
Oct 26, 2026
Muna BhanjiDirector
Stock award
22,500
Jun 9, 2026
William J. ChaseDirector
Stock award
22,500
Jun 9, 2026
Fred E. CohenDirector
Stock award
22,500
Jun 9, 2026
Brian GoffDirector
Stock award
22,500
Jun 9, 2026
Jesse GoodmanDirector
Stock award
22,500
Jun 9, 2026
Georgia KerestyDirector
Stock award
22,500
Jun 9, 2026
Frank VerwielDirector
Stock award
22,500
Jun 9, 2026
John M. LeonardPresident and CEO
Stock award
156,400
Mar 1, 2026
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
STOCK Act10 disclosures of 10 on record · median 12d of the 45 allowed
Congress trades in NTLA
Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
-31.8%since the tradeEstimated entry price $16.72, close on Mon Dec 9, 2019Current price $11.41, close on Wed Nov 11
Dec 9, 2019
Dec 14, 2019
5d
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.
A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.
What the filings on NTLA show and how current they are.
Are insiders buying or selling NTLA?
Across the 7 most recent open-market filings shown here, 0 were purchases and 7 were sales. 4 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded NTLA?
Donald S. Beyer, Jr. disclosed NTLA transactions in the filings shown here.
How quickly are NTLA trades disclosed?
Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 12 days, against the 45 the STOCK Act allows.